Boosting NAD+ levels through fasting to aid in COVID-19 recovery

Pharmacological therapy has played a vital role in combating various diseases, with dozens of novel drugs being approved each year. In the wake of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 outbreaks, scientists and researchers have been in a race against time to develop vaccines, discover new drugs, and repurpose old drugs for COVID-19. As of now, several drugs have been approved for the treatment of COVID-19 (1). COVID-19 is anticipated to transition into an endemic state, signifying its enduring presence within the population. However, this does not negate the potential for the virus to undergo evolutionary changes that could lead to sporadic outbreaks or seasonal surges. Even the World Health Organization (WHO) has recently issued standing recommendations that outline critical actions supporting the transition from emergency response to COVID-19 into strengthened and integrated infectious disease prevention and control programs (2). The goal is to prepare for potential worsening situations caused by new variants of the virus and to reduce the disease burden from COVID-19, which include addressing post-COVID-19 conditions such as long COVID.